NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Clinical Trials
17
Data completeness
3/8 — Basic
HALOPERIDOL (haloperidol) by Sagent Pharmaceuticals is clinical pharmacology the precise mechanism of action has not been clearly established. Approved for schizophrenia, bipolar disorder, schizoaffective disorder and 8 more indications.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Haloperidol is a first-generation antipsychotic available as an injectable formulation used to treat schizophrenia, bipolar disorder, psychotic disorders, and acute agitation. The precise mechanism of action has not been clearly established, though it is believed to involve dopamine antagonism. It is indicated for a broad range of psychiatric and non-psychiatric conditions including delirium, migraine headaches, nausea, and drug-induced movement disorders.
Pre-Launch
Pre-launch status indicates active commercial preparation and team expansion opportunities; likely recruiting for launch roles across medical affairs, regulatory, and field teams.
Mechanism of Action
CLINICAL PHARMACOLOGY The precise mechanism of action has not been clearly established.
Worked on HALOPERIDOL at Sagent Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.